Literature DB >> 24918326

On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy.

Qing Liu1, Yulan Li, Katherine Odem-Davis.   

Abstract

The regulatory guidelines on noninferiority (NI) trials emphasize constancy not only in the treatment effect over time but also in the trial design, clinical practice, and quality of the trial conduct and execution. In practice, the constancy assumption is generally impossible to justify; often, there are clear reasons to expect a loss of efficacy over time. There are also concerns about the inherent and publication bias in the historical data, and various sources of selection bias in the NI trial design. Thus, a conservative NI margin is often considered. However, different NI margin approaches are largely evaluated under the assumption of constancy and absence of bias, and therefore, controversies arise and are unresolved on the necessary degree of conservativeness. We develop a framework to quantify the robustness of any NI margin approach against inherent and publication bias in historical data, selection bias in trial design, and nonconstancy in reference effects. We introduce a consistency principle to address variability in the historical data. We control across-trial conditional error rates given a final NI trial design over a design specific robust range for reference effects. Following a conditionality principle, we provide a theoretical justification of the framework and the conditions for controlling across-trial unconditional type 1 error rates. We raise the issue of inherent bias in historical data with an illustrative example.

Entities:  

Keywords:  Across-trial conditional type 1 error rate; Lower predictive confidence bound; Retention of effect; Synthesis approach

Mesh:

Substances:

Year:  2015        PMID: 24918326      PMCID: PMC4263690          DOI: 10.1080/10543406.2014.923738

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  15 in total

1.  Design and analysis of non-inferiority mortality trials in oncology.

Authors:  Mark Rothmann; Ning Li; Gang Chen; George Y H Chi; Robert Temple; Hsiao-Hui Tsou
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

2.  Blinded independent central review of the progression-free survival endpoint.

Authors:  Ohad Amit; Will Bushnell; Lori Dodd; Nancy Roach; Daniel Sargent
Journal:  Oncologist       Date:  2010

3.  Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.

Authors:  Qing Liu; George Y H Chi
Journal:  J Biopharm Stat       Date:  2010-11       Impact factor: 1.051

4.  Some essential considerations in the design and conduct of non-inferiority trials.

Authors:  Thomas R Fleming; Katherine Odem-Davis; Mark D Rothmann; Yuan Li Shen
Journal:  Clin Trials       Date:  2011-08       Impact factor: 2.486

5.  Type I error probabilities based on design-stage strategies with applications to noninferiority trials.

Authors:  Mark Rothmann
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

6.  Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.

Authors: 
Journal:  Stat Med       Date:  2006-05-30       Impact factor: 2.373

7.  Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.

Authors:  H M James Hung; Sue-Jane Wang; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

8.  On the lower predictive bound approach for noninferiority clinical trials with binary data.

Authors:  Qing Liu; Yulan Li
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

9.  Bias in analytic research.

Authors:  D L Sackett
Journal:  J Chronic Dis       Date:  1979

10.  Adjusting for unknown bias in non-inferiority clinical trials.

Authors:  Katherine Odem-Davis; Thomas R Fleming
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

View more
  2 in total

1.  Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.

Authors:  Joseph S Koopmeiners; Brian P Hobbs
Journal:  Stat Methods Med Res       Date:  2016-09-01       Impact factor: 3.021

2.  A note on the determination of non-inferiority margins with application in oncology clinical trials.

Authors:  Binbing Yu; Harry Yang; Antony Sabin
Journal:  Contemp Clin Trials Commun       Date:  2019-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.